AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03869944
Drug: Lamivudine Oral Solution
RxNorm normalized name: Lamivudine Oral Solution
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: During the EPI-2 visit, HIV-1 negative children of mothers with a unsuppressed plasma HIV-1 VL (≥ 1000 copies/mL) will be initiated on PrEP, lamivudine syrup (7.5 mg twice daily if 2 to 4 kg; 25 mg twice a day if weight \<8 kg; and 50 mg twice a day if weight \>8 kg) for 10 months, until the child is 12 months old. A monitoring on the mother's VL and child's diagnosis will take place at 6 and 12 months.~Mothers with unsuppressed plasma HIV-1 VL (\< 1000 copies/mL) and HIV-1 negative children will not be offered PrEP but the mother's VL and child diagnosis will be monitored at 6 and 12 months: If the VL is ≥ 1000 copies/mL, the child will be initiated on PrEP until the child is 12 months old.~Children infected with HIV-1 will be referred to the National Program for immediate ART.
Trial: NCT02920801
Drug: saxagliptin
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg per day for 12 weeks
Trial: NCT02920801
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1500mg per day for 12 weeks
Trial: NCT00307086
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: the maximum tolerated dose (MTD) of bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous stem cell transplant
Trial: NCT00307086
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day -4 melphalan 100 mg/m2 intravenously over 30 minutes, Day -3 melphalan 100 mg/m2 intravenously over 30 minutes
Trial: NCT01354444
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: target dose of 25 mg daily which is half the maximum dose used in clinical practice
Trial: NCT04334317
Drug: TAK-071
RxNorm normalized name: TAK-071
DrugBank: TAK-071 (DB18954)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-071 tablet.
Trial: NCT00147719
Drug: Colesevelam hydrochloride
RxNorm normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05485818
Drug: Middle Dose
RxNorm normalized name: wheat middlings extract
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12±4 hours after PCI: 0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
Trial: NCT02263963
Drug: Exparel
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In this arm as described above the intervention will be TAP block injection under ultrasound guidance using Exparel.
Trial: NCT00879086
Drug: Eribulin Mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: E7389 (eribulin mesylate) given at a dose of 1.4 mg/m\^2 as a 2 to 5 minute intravenous (IV) bolus on Days 1 and 8 of a 21-day cycle.~The Treatment Phase will include six cycles. Patients may enter the Extension Phase for additional cycles following the sixth cycle of treatment.
Trial: NCT00879086
Drug: Ixabepilone
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ixabepilone given at a starting dose of 32 or 40 mg/m\^2 (as per approved labeling) as a 3-hour IV infusion on Day 1 of a 21-day cycle.~The Treatment Phase will include six cycles. Patients may enter the Extension Phase for additional cycles following the sixth cycle of treatment.
Trial: NCT02969044
Drug: PF-06651600
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg pill every day (QD) for 8 weeks
Trial: NCT03153358
Drug: Icotinib
RxNorm normalized name: icotinib
DrugBank: Icotinib (DB11737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: icotinib 125 milligram three times a day
Trial: NCT00327418
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00890617
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone taken:~20mg BID on the day of the cryotherapy procedure 20mg BID on the day after the procedure 20mg BID two days after the procedure 20mg AM and 10mg PM three days after the procedure 10mg AM and 10mg PM four days after the procedure 10mg five days after the procedure 5mg six days after the procedure
Trial: NCT06030375
Drug: KAND567
RxNorm normalized name: KAND567
DrugBank: KAND567 (DB16511)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion for 6 hours
Trial: NCT04650204
Drug: Perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01683396
Drug: gevokizumab
RxNorm normalized name: Gevokizumab
DrugBank: Gevokizumab (DB12119)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for subcutaneous injection
Trial: NCT00681343
Drug: Thymoglobulin
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction
Trial: NCT00681343
Drug: Daclizumab
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Induction
Trial: NCT03903302
Drug: CS1-Sodium Valproate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single and multiple dose evaluation of CS1
Trial: NCT04356989
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The adminstration dose is decided by the attending physician in advance based on the patients' CrCl and in compliance with local market authorization of rivaroxaban.
Trial: NCT03308214
Drug: Imipenem
RxNorm normalized name: Imipenem
DrugBank: Imipenem (DB01598)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Imipenem 1.0 q 8h
Trial: NCT00312338
Drug: VIGAMOX
RxNorm normalized name: Vigamox
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 drop of VIGAMOX® ophthalmic solution 0.5% in both eyes TID for 7 days
Trial: NCT04968613
Drug: Madopar monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In addition to basic treatment, the patient also received Madopar treatment
Trial: NCT04968613
Drug: senfrol monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In addition to the basic treatment, the patient also received the rofosson treatment
Trial: NCT02501928
Drug: Fesoterodine PR 4 mg
RxNorm normalized name: fesoterodine fumarate 4 MG
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fesoterodine 4 mg tablet once daily for 28 or 40 weeks
Trial: NCT02501928
Drug: Fesoterodine PR 8 mg
RxNorm normalized name: fesoterodine fumarate 8 MG
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fesoterodine PR 8 mg tablet once daily for 28 or 40 weeks
Trial: NCT02501928
Drug: Fesoterodine BIC 4 mg
RxNorm normalized name: fesoterodine fumarate 4 MG
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fesoterodine BIC 4 mg tablet once daily for 28 weeks
Trial: NCT00929851
Drug: Formoterol fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol fumarate 12 µg per metered dose
Trial: NCT00036153
Drug: Tacrolimus (Prograf®)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00428272
Drug: Lexatumumab alone
RxNorm normalized name: Lexatumumab
DrugBank: Lexatumumab (DB06599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation : 3mg/kg, 5mg/kg, 8mg/kg, 10mg/kg
Trial: NCT00428272
Drug: Lexatumumab in combination
RxNorm normalized name: Lexatumumab
DrugBank: Lexatumumab (DB06599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation : 1mg/kg, 3mg/kg, 5mg/kg, 8mg/kg, 10mg/kg
Trial: NCT00428272
Drug: Interferon gamma 1b in combination
RxNorm normalized name: Interferon Gamma-1B
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing at the following for each lexatumumab dose level: .75mcg/m2/dose and 25mcg/m2/dose
Trial: NCT00428272
Drug: Gamma 1b potential expansion
RxNorm normalized name: Interferon Gamma-1B
DrugBank: Interferon gamma-1b (DB00033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potential expansion (at 10mg/kg lexatumumab): 1.5mcg/m2/dose and 50mcg/m2/dose
Trial: NCT01197911
Drug: aleglitazar
RxNorm normalized name: Aleglitazar
DrugBank: Aleglitazar (DB08915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT03106324
Drug: Revlimid (lenalidomide)
RxNorm normalized name: lenalidomide Oral Capsule [Revlimid]
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment with first line Revlimid containing regimen as prescribed in routine clinical practice
Trial: NCT06568224
Drug: Mesalazine
RxNorm normalized name: mesalazine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral mesalazine 1g qid
Trial: NCT02020278
Drug: Tolvaptan
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tolvaptan 3.75-, 7.5-, 15-, and 30-mg spray-dried tablets. Dosage: Depending on age and weight, Tablet (3.75 mg - 60 mg daily). Frequency: Once daily.~Duration: Participants may be eligible to receive short-term or long-term optional tolvaptan treatment at any time during their participation in the trial, with one or more treatment cycles over a 6-month period.
Trial: NCT01047254
Drug: Elontril
RxNorm normalized name: phendimetrazine tartrate Oral Tablet [Bontril]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: flexible dose of Bupropion 150-300 mg
Trial: NCT00346983
Drug: Pegaptanib sodium
RxNorm normalized name: Pegaptanib Sodium
DrugBank: Pegaptanib (DB04895)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.3mg/0.1ml intravitreal injection, every 6 weeks, up to a total of 3 injections
Trial: NCT00346983
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham injection, every 6 weeks, up to a total of 3 sham injections
Trial: NCT01097512
Drug: AS703569/gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine on Days 1 and 8, AS703569 on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.~Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle.
Trial: NCT01097512
Drug: AS703569/gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AS703569 on Days 1 and 8, gemcitabine on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.~Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle.
Trial: NCT01982955
Drug: Tepotinib
RxNorm normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tepotinib was administered at a dose range of 300 or 500 milligram (mg) (Phase 1b) and the recommended phase II dose (RP2D) determined in the Phase 1b in Phase II orally once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment. RP2D was determined as per safety monitoring committee (SMC) discretion.
Trial: NCT01982955
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gefitinib was administered at a dose of 250 mg orally as once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment.
Trial: NCT01982955
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed was administered at a dose of 500 milligram per square meter (mg/m\^2) as intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
Trial: NCT01982955
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin was administered at a dose of 75 mg/m\^2 as intravenous infusion over 2 hours on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
Trial: NCT01982955
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin was administered intravenously on Day 1 of each 21-day cycle at a dose of area under curve (AUC) 5 or AUC6 at the discretion of the Investigator until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
Trial: NCT00768248
Drug: perineural ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ropivacaine 0.4%; the basal rate will be set at 7 mL/h
Trial: NCT00768248
Drug: normal saline (placebo)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the basal rate will be set at 7 mL/h
Trial: NCT00710268
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV administration10 mg/kg every 14 days
Trial: NCT02063568
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02601014
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: given orally per standard of care
Trial: NCT00317629
Drug: meglumine antimoniate
RxNorm normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg/kg daily during 20 days
Trial: NCT00277329
Drug: XL999
RxNorm normalized name: XL999
DrugBank: XL999 (DB05014)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • The Study Treatment Period, in which subjects received a once-weekly, 4-hour intravenous (IV) infusion of XL999 at 2.4 mg/kg as outpatients for 8 weeks. Treatment was to be stopped at the occurrence of disease progression or unacceptable toxicity.
Trial: NCT03145675
Drug: Enoxaparin (Staged-dose PCI Group)
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 0.5+0.25 mg/kg administered intravenously.
Trial: NCT03145675
Drug: Enoxaparin (Single-dose PCI Group)
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 0.75 mg/kg administered intravenously.
Trial: NCT03145675
Drug: Enoxaparin (High-dose Group)
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 0.75 mg/kg administered intravenously.
Trial: NCT03145675
Drug: Enoxaparin (Standard-dose Group)
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 0.5 mg/kg administered intravenously.
Trial: NCT00676702
Drug: Pancrelipase in combination with Ensure Plus
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 pancrelipase MT 21 capsules containing a total of 63,000 USP units of lipase with a high-fat liquid meal of 500 ml of Ensure Plus.
Trial: NCT01259479
Drug: Satraplatin
RxNorm normalized name: Satraplatin
DrugBank: Satraplatin (DB04996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally, once daily for 5 days repeated every 28 days, dose-escalation
Trial: NCT00029003
Drug: gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT03654833
Drug: Rucaparib
RxNorm normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PARP inhibitor
Trial: NCT03654833
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CDK4/6 inhibitor
Trial: NCT03654833
Drug: pembrolizumab & bemcentinib
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PD1 checkpoint inhibitor, AXL inhibitor
Trial: NCT03654833
Drug: Atezolizumab & Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PDL1 checkpoint inhibitor, VEGF inhibitor
Trial: NCT03654833
Drug: Dostarlimab and Niraparib
RxNorm normalized name: Dostarlimab
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IG Antibody, PARP Inhibitor
Trial: NCT03744247
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.
Trial: NCT03744247
Drug: PD-1 antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mg/kg intravenously every 2 weeks
Trial: NCT00870844
Drug: Lu AA24493 (CEPO)
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 to 50.0 mcg/kg body weight, IV, within 0 to 48 hrs from symptom onset
Trial: NCT00366795
Drug: Satavaptan
RxNorm normalized name: Satavaptan
DrugBank: Satavaptan (DB14923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration once daily
Trial: NCT01891864
Drug: GP2015 Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sandoz has developed GP2015 Etanercept (Sandoz's code for the drug product containing the active ingredient etanercept) to be biosimilar to Enbrel.
Trial: NCT01891864
Drug: Enbrel
RxNorm normalized name: Enbrel
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Enbrel is used as reference product to GP2015.
Trial: NCT03906799
Drug: OMT-28
RxNorm normalized name: Omtryg
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days).
Trial: NCT00499005
Drug: Syntommetrine and Carbetocin
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Carbetocin (DB01282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syntommetrine 1ml and Carbetocin 100microgram
Trial: NCT00499005
Drug: Syntommetrine and Carbetocin
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Carbetocin (DB01282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syntommetrine 1ml and Carbetocin 100micgrams
Trial: NCT04825392
Drug: HX008
RxNorm normalized name: Immunoglobulin g4 (252-theronine,306-proline,432-alanine), anti-(human programmed cell death 1) (human-mus musculus monoclonal hx008 .gamma.4-chain), disulfide with human-mus musculus monoclonal hx008 .kappa.-chain, dimer
DrugBank: Pucotenlimab (DB17552)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive HX008 3mg/kg by intravenous (IV) infusion on Day 1, every 3 weeks (Q3W), till progressed disease or withdrawal.
Trial: NCT00772863
Drug: docetaxel and cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 cycles Cisplatin 100 mg/m2 at every 3 weeks, after Cisplatin 4 cycles of docetaxel 100mg/m2 at every 3 weeks
Trial: NCT00128440
Drug: tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02046044
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02046044
Drug: Ivabradine
RxNorm normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02142790
Drug: paclitaxel liposome injection
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02398266
Drug: Contrast ultrasound of leg muscle with Sonazoid (Contrast ultrasound microvascular perfusion imaging)
RxNorm normalized name: Crab leg
DrugBank: Crab leg (DB11011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skeletal muscle perfusion assessment of the thigh and calf skeletal muscle will be performed with contrast ultrasound of leg muscle with Sonazoid while at rest and during exercise stress
Trial: NCT00753038
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
Trial: NCT00753038
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle
Trial: NCT00226577
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (GemzarR) 1500 mg/m2